动物疫苗板块持续拉升，申联生物涨超10%，科兴制药、金河生物（002688）、蔚蓝生物（603739）、 康华生物（300841）、海利生物（603718）跟涨。 暗盘资金正涌入这些股票，点击速看>>> ...

Core Viewpoint - Company has signed cooperation contracts with the Lanzhou Veterinary Research Institute and Zhongnong Weite Biotechnology Co., Ltd. to develop multi-valent vaccines for swine and cattle, addressing the urgent market demand for complex animal disease prevention [1][2][3] Group 1: Cooperation Details - The contracts include the development of two multi-valent vaccines: one for swine (foot-and-mouth disease, swine fever, and pseudorabies) and one for cattle (foot-and-mouth disease, viral diarrhea/mucosal disease, and infectious bovine rhinotracheitis) [1][2] - The cooperation involves shared responsibilities and costs among the parties, with joint ownership of the resulting intellectual property [1][5][8] Group 2: Technical Goals and Methods - The technical goals include obtaining clinical trial approval and new veterinary drug registration for both vaccine projects [3][6] - The development process will follow the Ministry of Agriculture and Rural Affairs' requirements, including research on strains, production processes, and clinical trials [4][6] Group 3: Impact on the Company - This collaboration reflects the company's focus on advanced biotechnology and aims to enhance its competitive position in the animal health sector by providing comprehensive disease prevention solutions [8][9] - The vaccines are designed to reduce the number of immunizations required, thereby saving resources and costs while improving production efficiency [8][9] Group 4: Future Directions - The company plans to strengthen its collaboration with the Lanzhou Veterinary Research Institute and explore the application potential of its research technology platform for other vaccine developments, including mRNA and VLPs vaccines [9]

《科创板日报》7月31日讯 今日科创板晚报主要内容包括：国常会审议通过《关于深入实施"人工智能 +"行动的意见》；国家医保局支持脑机接口等新技术进入临床并收费；特斯拉将Robotaxi服务范围扩大 至加州湾区。 【热点聚焦】 简讯： 国常会审议通过《关于深入实施"人工智能+"行动的意见》 据央视新闻报道，国务院总理李强7月31日主持召开国务院常务会议，会议审议通过《关于深入实施"人 工智能+"行动的意见》。会议指出，当前人工智能技术加速迭代演进，要深入实施"人工智能+"行动， 大力推进人工智能规模化商业化应用，充分发挥我国产业体系完备、市场规模大、应用场景丰富等优 势，推动人工智能在经济社会发展各领域加快普及、深度融合，形成以创新带应用、以应用促创新的良 性循环。政府部门和国有企业要强化示范引领，通过开放场景等支持技术落地。要着力优化人工智能创 新生态，强化算力、算法和数据供给，加大政策支持力度，加强人才队伍建设，构建开源开放生态体 系，为产业发展壮大提供有力支撑。要提升安全能力水平，加快形成动态敏捷、多元协同的人工智能治 理格局。 国家发改委：推动"人工智能+"行动走深走实 推进低空经济高质量发展 国家发展 ...

本报讯 （记者金婉霞）7月31日，申联生物医药（上海）股份有限公司（以下简称"申联生物"）公告 称，近日，公司与中国农业科学院兰州兽医研究所（以下简称"兰研所"）等单位签订了项目合同，拟共 同开发猪用口蹄疫等三种疫病多联多价疫苗及牛用口蹄疫等三种疫病多联多价疫苗，合作各方按照协议 约定任务和分工，各自承担相关费用，合作研发项目产生的技术成果及知识产权归公司及兰研所两方共 同享有。 （编辑 张文玲 郭之宸） 申联生物方面表示，拟开发的疫苗预期可实现"一针四防"，有效减少免疫次数，节约免疫资源和防疫成 本，提升生产效率，具备较强的市场竞争力，将有助于公司为客户提供更全面、高效的疫病防控解决方 案，将进一步提升公司在动保领域的技术领先地位。未来，申联生物将持续加强与兰研所的深度合作， 紧跟行业发展趋势，精准把握流行毒株变化和临床需求，进一步挖掘研发技术平台体系的应用潜力，加 速推进其他多联多价疫苗、mRNA疫苗、合成肽疫苗、病毒样颗粒（VLPs）疫苗等新产品的技术突破 与产业化落地，在猪用、反刍用、宠物用、水产用等疫病防治领域逐步形成集群化产品矩阵，不断提升 公司核心竞争力。 ...

证券之星消息，7月31日动物保健板块较上一交易日下跌0.43%，大禹生物领跌。当日上证指数报收于 3573.21，下跌1.18%。深证成指报收于11009.77，下跌1.73%。动物保健板块个股涨跌见下表： 从资金流向上来看，当日动物保健板块主力资金净流出1611.97万元，游资资金净流出6281.9万元，散户 资金净流入7893.87万元。动物保健板块个股资金流向见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 300871 回盛生物 | | 6787.00万 | 7.85% | -4042.91万 | -4.68% | -2744.09万 | -3.17% | | 600201 | 生物股份 | 2619.98万 | 9.14% | -534.51万 | -1.86% | -2085.47万 | -7.28% | | 002868 *ST绿康 | | 940.97万 | 10.50% | -518.20 ...

证券代码：688098 证券简称：申联生物 公告编号：2025-026 申联生物医药（上海）股份有限公司 关于与中国农业科学院兰州兽医研究所 签订多联多价疫苗项目合作开发合同的 自愿性披露公告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 近日，申联生物医药（上海）股份有限公司（以下简称"公司"）与中 国农业科学院兰州兽医研究所（以下简称"兰研所"）等单位签订了《猪口蹄疫 O 型/A 型、猪瘟、伪狂犬病三联疫苗技术开发（合作）合同》及《牛口蹄疫 O 型/A 型、病毒性腹泻/黏膜病、传染性鼻气管炎三联疫苗技术开发（合作）合同》， 共同开发猪用口蹄疫等三种疫病多联多价疫苗及牛用口蹄疫等三种疫病多联多 价疫苗，合作各方按照协议约定任务和分工，各自承担相关费用，合作研发项目 产生的技术成果及知识产权归公司及兰研所两方共同享有。 风险提示：本次合作研发属于新项目、新技术的研究开发。尽管在前期 的研究中已对两款产品进行了初步的安全性与有效性试验，但上述两款口蹄疫等 三种疫病多联多价疫苗产品最终能否通过农业农村部的行政审 ...

申联生物(688098.SH)公告，公司与中国农业科学院兰州兽医研究所等单位签订了《猪口蹄疫O型/A型、 猪瘟、伪狂犬病三联疫苗技术开发(合作)合同》及《牛口蹄疫O型/A型、病毒性腹泻/黏膜病、传染性鼻 气管炎三联疫苗技术开发(合作)合同》，共同开发猪用口蹄疫等三种疫病多联多价疫苗及牛用口蹄疫等 三种疫病多联多价疫苗，合作各方按照协议约定任务和分工，各自承担相关费用，合作研发项目产生的 技术成果及知识产权归公司及兰研所两方共同享有。 ...

Core Viewpoint - The company, Shenlian Biological (688098), has signed cooperative contracts with the Lanzhou Veterinary Research Institute of the Chinese Academy of Agricultural Sciences to develop multi-valent vaccines for swine and cattle diseases [1] Group 1: Vaccine Development Contracts - The company has entered into two contracts for the technical development of vaccines: one for swine diseases including foot-and-mouth disease (O-type/A-type), swine fever, and pseudorabies, and another for cattle diseases including foot-and-mouth disease (O-type/A-type), viral diarrhea/mucosal disease, and infectious bovine rhinotracheitis [1] - The collaboration involves shared responsibilities and costs among the parties involved, with the resulting technological achievements and intellectual property being jointly owned by the company and the Lanzhou Veterinary Research Institute [1]

Core Viewpoint - The company has signed cooperative contracts with the Lanzhou Veterinary Research Institute of the Chinese Academy of Agricultural Sciences and other units to develop multi-valent vaccines for swine and cattle, focusing on several significant diseases [1] Group 1: Vaccine Development Contracts - The company has entered into a contract for the technical development of a tri-valent vaccine for swine, targeting foot-and-mouth disease (FMD) types O and A, swine fever, and pseudorabies [1] - Additionally, a contract has been signed for the development of a tri-valent vaccine for cattle, addressing FMD types O and A, viral diarrhea/mucosal disease, and infectious bovine rhinotracheitis [1] - The collaboration involves shared responsibilities and costs among the parties, with the resulting technological achievements and intellectual property being jointly owned by the company and the Lanzhou Veterinary Research Institute [1]

申联生物：与兰州兽医研究所签订多联多价疫苗项目合作开发合同 《科创板日报》31日讯，申联生物(688098.SH)公告称，公司与兰州兽医研究所等单位签订两份技术开 发（合作）合同，共同开发猪用和牛用口蹄疫等三种疫病多联多价疫苗。合作产生的技术成果及知识产 权归公司及兰研所两方共同享有。尽管两款产品已进行初步安全性与有效性试验，但能否通过农业农村 部审批及具体上市时间存在不确定性。 ...